Sinocare Valuation Multiples

Discover Sinocare's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Weigao Group, Nolato, Vitrolife, Conmed and more.

Sinocare Overview

About Sinocare

Sinocare Inc operates in the healthcare industry. It is engaged in the development, manufacturing, and marketing of diagnosis testing products for people with chronic diseases and healthcare professionals. Its product range covers household blood glucose meter, medical blood glucose meter, urinary microalbumin test strip and blood lipid uric acid products. In addition, the company also provides diabetes management information systems.


Founded

2002

HQ

China

Employees

N/A

Financials (LTM)

Revenue: $719M
EBITDA: $79M

EV

$1.3B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Sinocare Financials

Sinocare reported last 12-month revenue of $719M and EBITDA of $79M.

In the same LTM period, Sinocare generated $364M in gross profit, $79M in EBITDA, and $37M in net income.

Revenue (LTM)


Sinocare P&L

In the most recent fiscal year, Sinocare reported revenue of $688M and EBITDA of $57M.

Sinocare is profitable as of last fiscal year, with gross margin of 49%, EBITDA margin of 8%, and net margin of 2%.

See analyst estimates for Sinocare
LTMLast FY202320242025202620272028
Revenue$719M$688M$599M$656M$688M
Gross Profit$364M$335M$324M$360M$335M
Gross Margin51%49%54%55%49%
EBITDA$79M$57M$77M$97M$46M
EBITDA Margin11%8%13%15%7%
EBIT Margin5%6%11%12%6%
Net Profit$37M$14M$42M$48M$14M
Net Margin5%2%7%7%2%

Financial data powered by Morningstar, Inc.

Sinocare Stock Performance

Sinocare has current market cap of $1.3B, and enterprise value of $1.3B.

Market Cap Evolution


Sinocare's stock price is $2.31.

Sinocare share price increased by 12.5% in the last 30 days, and decreased by 23.9% in the last year.

Sinocare has an EPS (earnings per share) of $0.02.

See more trading valuation data for Sinocare
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1.3B$1.3B0.0%12.5%-5.0%-23.9%$0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Sinocare Valuation Multiples

Sinocare trades at 1.8x EV/Revenue multiple, and 16.2x EV/EBITDA.

See NTM and 2027E valuation multiples for Sinocare

EV / Revenue (LTM)


Sinocare Financial Valuation Multiples

As of July 19, 2026, Sinocare has market cap of $1.3B and EV of $1.3B.

Sinocare has a P/E ratio of 35.1x.

LTMLast FY202320242025202620272028
EV/Revenue1.8x1.9x2.1x1.9x1.9x
EV/EBITDA16.2x22.4x16.7x13.1x27.9x
EV/EBIT32.3x29.6x18.8x16.6x29.6x
EV/Gross Profit3.5x3.8x3.9x3.5x3.8x
P/E35.1x94.1x30.6x26.7x94.1x
EV/FCF-21.3x22.3x19.5x21.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Sinocare Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Sinocare Margins & Growth Rates

Sinocare grew revenue by 9% and EBITDA by 70% in the last fiscal year.

In the most recent fiscal year, Sinocare reported gross margin of 49%, EBITDA margin of 8%, and net margin of 2%.

See estimated margins and future growth rates for Sinocare

Sinocare Margins

Last FY202420252026202720282029
Gross Margin49%55%49%52%
EBITDA Margin8%15%7%13%
EBIT Margin6%12%6%9%
Net Margin2%7%2%7%
FCF Margin9%10%9%-

Sinocare Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth9%9%5%9%
Gross Profit Growth16%11%(7%)16%
EBITDA Growth70%27%(53%)112%
EBIT Growth49%14%(44%)49%
Net Profit Growth307%15%(72%)307%
FCF Growth-14%(9%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Sinocare Operational KPIs

Sinocare's Rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sinocare's Rule of X is 35% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Sinocare
LTMLast FY202320242025202620272028
Rule of 4021%22%---
Bessemer Rule of X36%35%---
S&M Expenses to Revenue27%27%15%17%16%
G&A Expenses to Revenue10%10%4%4%4%
R&D Expenses to Revenue6%6%9%8%6%
Opex to Revenue-42%43%43%42%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Sinocare Competitors

Sinocare competitors include Weigao Group, Nolato, Vitrolife, Conmed, Alphatec Holdings, Haier Biomedical, Staar Surgical, iRadimed, VCANBIO and 4DMedical.

Most Sinocare public comparables operate across Medical Devices, Medical Imaging & Diagnostics, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Weigao Group4.7x4.4x13.4x13.9x
Nolato1.3x1.4x7.8x8.1x
Vitrolife3.6x3.7x12.4x12.1x
Conmed1.5x1.6x7.7x7.8x
Alphatec Holdings2.3x2.1x19.0x15.3x
Haier Biomedical3.1x2.9x18.1x17.5x
Staar Surgical3.6x4.1x20.2x40.6x
iRadimed14.2x13.5x43.5x40.2x

This data is available for Pro users. Sign up to see all Sinocare competitors and their valuation data.

Start Free Trial

Acquisitions by Sinocare

Sinocare has acquired 2 companies to date.

Last acquisition by Sinocare was on May 3rd 2016. Sinocare acquired Polymer Technology Systems, Inc for $200M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Sinocare

Polymer Technology Systems, Inc
Trividia Health
Description
Polymer Technology Systems, Inc. is an Indiana-based developer of point-of-care diagnostics under PTS Diagnostics, producing rapid tests for cholesterol, lipids, glucose, and kidney function. FDA-clebotomy cleared products like CardioChek and A1CNow serve clinics and pharmacies, with distribution in 50 countries since 1989.
Trividia Health is a Fort Lauderdale-headquartered developer and manufacturer of diabetes management products including blood glucose meters and test strips. Formerly Nipro Diagnostics, the company operates production facilities in Florida, New Hampshire, and Taiwan to supply global markets with monitoring technologies.
HQ CountryUnited StatesUnited States
HQ City
Indianapolis, IN
Fort Lauderdale, FL
Deal Date3 May 201627 Oct 2015
Valuation$200M$273M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Sinocare acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Sinocare

Sinocare has invested in 1 company to date.

Latest investment by Sinocare was on February 18th 2021. Sinocare invested in SPH Health Commerce in their $160M Series B round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Sinocare

SPH Health Commerce
Description
-
HQ CountryChina
HQ City
-
Deal Date18 Feb 2021
RoundSeries B
Raised$160M
InvestorsHuadong Industrial; Shanghai Minority Asset Management; New Alliance Capital; JIC Investment; Sinocare; Shanghai Biomedical Industrial Equity Investment Fund; Ample Harvest Finance
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Sinocare investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Sinocare

When was Sinocare founded?Sinocare was founded in 2002.
Where is Sinocare headquartered?Sinocare is headquartered in China.
Is Sinocare publicly listed?Yes, Sinocare is a public company listed on Shenzhen Stock Exchange.
What is the stock symbol of Sinocare?Sinocare trades under 300298 ticker.
When did Sinocare go public?Sinocare went public in 2012.
Who are competitors of Sinocare?Sinocare main competitors include Weigao Group, Nolato, Vitrolife, Conmed, Alphatec Holdings, Haier Biomedical, Staar Surgical, iRadimed, VCANBIO, 4DMedical.
What is the current market cap of Sinocare?Sinocare's current market cap is $1.3B.
What is the current revenue of Sinocare?Sinocare's last 12 months revenue is $719M.
What is the current revenue growth of Sinocare?Sinocare revenue growth (NTM/LTM) is 10%.
What is the current EV/Revenue multiple of Sinocare?Current revenue multiple of Sinocare is 1.8x.
What is the current EBITDA of Sinocare?Sinocare's last 12 months EBITDA is $79M.
What is Sinocare's EBITDA margin?Sinocare's last 12 months EBITDA margin is 11%.
What is the current EV/EBITDA multiple of Sinocare?Current EBITDA multiple of Sinocare is 16.2x.
How many companies Sinocare has acquired to date?As of July 2026, Sinocare has acquired 2 companies.
What was the largest acquisition by Sinocare?$273M acquisition of Trividia Health on 27th October 2015 was the largest M&A Sinocare has done to date.
What companies Sinocare acquired?Sinocare acquired Trividia Health and Polymer Technology Systems, Inc.
In how many companies Sinocare has invested to date?As of July 2026, Sinocare has invested in 1 company.
What was the last Sinocare investment?On 18th February 2021 Sinocare invested in SPH Health Commerce, participating in a $160M Series B round, alongside Huadong Industrial, Shanghai Minority Asset Management, New Alliance Capital, JIC Investment, Shanghai Biomedical Industrial Equity Investment Fund, and Ample Harvest Finance.
In what companies Sinocare invested in?Sinocare invested in SPH Health Commerce.

See public comps similar to Sinocare

Lists including Sinocare

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial